CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FTSE flat as traders eye developments in Europe ahead of Summit

Article By: ,  Financial Analyst

The FTSE 100 closed flat on the day after a choppy trading session that saw some investors move to diversify their equity risk by offloading holdings in banks and miners and recycling those funds into defensive sectors such as pharmaceutical and tobacco stocks in a defensive move in case of a Summit disappointment.

The FTSE 100 in fact outperformed broader European indices largely thanks to the heavyweight bearings on the UK Index from pharmaceutical stocks, which were the main gainers on the day. The German DAX fell 1.27% whilst the French CAC fell 0.7% on the day.

The move by ratings agency Standard & Poor’s last night to place 15 of the 17 single currency states on a negative watch for a potential downgrade in ratings over the next 90 days depending on the outcome of the EU Summit did put a bit of a dampener on trading today. Whilst the move was of little surprise given the importance of the Summit in Brussels, it did give both politicians and traders a timely reminder as to just how high the stakes are for the output of the Summit itself and whether it does enough to convince investors that the crisis is being managed.

Indeed, much could depend on whether or not a fiscal compact can be reached, and if this is enough to trigger the ECB into action.

Trading on the day was particularly choppy, with the FTSE 100 swinging between a narrow trading range of just 1% as investors mostly sat on the sidelines awaiting developments out of the euro region that may help them to gauge the likely output of the Summit at the end of the week.

Wolseley was the top performing stock of the day, with shares rallying 3.6% after the building services firm reported a 16% rise in first quarter profits. This triggered brokers into upgrading their stances on the firms’ shares, with Seymour Pierce re-rating the firm as a buy from an original hold stance, citing a stronger than expected performance in the US.

Closely following Wolseley were shares of Sage, which rose 2.2% and Weir Group, whose shares rallied 2.1% on the day.

Antofagasta and GlaxoSmithKline, the heavyweight pharmaceutical firms, benefitted the most from investors recycling their portfolio risk out of mining and banking stocks, with both firms’ share prices seeing gains of 2%.

The biggest faller on the day was Meggitt, after investors sold out of the aerospace and defence firms shares following a Credit Suisse ratings cut to underperform from outperform. The broker cited that whilst they expected robust full-year results for the year, they were more cautious about the firm’s civil aftermarket and military end markets in 2012 and 2013, which contributes roughly 70% of revenues. Shares fell 4.4% on the day as a result.

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.

City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.

City Index is a trademark of StoneX Financial Ltd.

The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.

© City Index 2024